Related Experiment Videos
Continuous bromocriptine therapy in menstrual migraine
1Neuroendocrine Unit, Charles A. Dana Research Institute, Beth Israel Hospital, Boston, MA 02215, USA.
Neurology
|January 1, 1997
Summary
Continuous bromocriptine therapy significantly reduced menstrual migraine frequency in a prospective trial. This treatment proved more effective than baseline therapy and intermittent use for disabling migraines.
Area of Science:
- Neurology
- Pharmacology
Background:
- Menstrual migraine is a disabling condition impacting many women.
- Existing treatments for menstrual migraine are often insufficient.
Purpose of the Study:
- To evaluate the efficacy of adjunctive continuous bromocriptine therapy for refractory menstrual migraine.
- To compare continuous bromocriptine with prior optimal therapy and cyclic use.
Main Methods:
- An open, prospective trial involving 24 women with disabling menstrual migraine.
- Bromocriptine (2.5 mg three times daily) was added to existing regimens.
- Menstrual migraine frequency was compared before and during the first year of bromocriptine therapy.
Main Results:
- Eighteen of 24 women (75%) experienced a ≥25% reduction in migraine frequency.
- Overall migraine frequency decreased by 72% (p < 0.01).
- Continuous bromocriptine was significantly more effective than intermittent use (p < 0.05).
Conclusions:
- Adjunctive continuous bromocriptine therapy is effective for reducing the frequency of disabling menstrual migraine.
- The treatment is well-tolerated, with most participants showing significant improvement.